MedinCell has seen its share price move sharply in recent years, and the latest headlines around its U.S. product launch plans put fresh attention on whether today's valuation is still grounded in the revenue it generates. With the stock now in focus again, the key issue is how its current market value lines up with its sales profile.
-
MedinCell has delivered a very large 3 year share price gain of about 3.5x, which puts real pressure on the question of whether its present market capitalization can be explained by its sales base.
-
The recent FDA approval of its long acting injectable olanzapine treatment WELTRUZA and planned U.S. launch with Teva may support higher future sales expectations and reshape how investors think about the relationship between its current share price and reported revenue.
-
There is a second opinion on MedinCell worth weighing. See what analysts think MedinCell's shares could be worth .
The stock's next move may depend on whether MedinCell's current share price can be reasonably linked to its sales when set against the Fair Ratio benchmark.
If you want to test the same sales based valuation question beyond MedinCell, run the numbers across a wider field using 180 high quality undervalued stocks .
Has MedinCell Run Too Far on Sales?
P/S fits MedinCell because investors are currently focused on what it earns from its products rather than accounting profits. On that yardstick, the stock trades on a P/S of about 42.6x, compared with roughly 2.7x for the wider Pharmaceuticals industry and around 1.7x for its closest listed peers, so buyers are paying a far higher price for each euro of sales than is typical in the sector.
The tailored Fair Ratio framework, which factors in MedinCell's growth profile, margins, size and risk, also flags the current P/S as overvalued, and the gap is wide enough that the model reads more like a valuation warning than a precise target. Despite the recent FDA approval of WELTRUZA and the planned U.S. launch with Teva lifting expectations, the share price still embeds a very rich top line multiple that assumes a lot about how future revenue will justify today's tag. Explore the numbers behind MedinCell's P/S valuation .
The MedinCell Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the MedinCell valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to play out for the stock to end up worth materially more or less than today's price. Each scenario focuses on the assumptions behind its fair value so you can compare those expectations with MedinCell's actual results as they are reported over time on the Community page.
One of the top community narratives on MedinCell: 18% undervalued
"MedinCell's demonstrated ability to secure large-scale partnerships and expansion into emerging global markets position it to capture rising demand..."
Discover why this Narrative puts MedinCell at 18% undervalued .
One more MedinCell thread that could change how you see the price
There is a separate lens investors often check before acting on any valuation work. This is where professional analysts currently see MedinCell a few years out. Explore where analysts expect MedinCell to be in a few years .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MEDCL.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
